00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:26 , Jun 21, 2019 |  BC Extra  |  Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease  AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting...
00:31 , Jun 4, 2019 |  BC Innovations  |  Distillery Therapeutics

Dual inhibition of CDK4 and CDK6 for pulmonary arterial hypertension

DISEASE CATEGORY: Cardiovascular INDICATION: Hypertension Patient sample and rat studies suggest dual inhibition of CDK4 and CDK6 could help treat pulmonary arterial hypertension (PAH). In lung samples from patients with idiopathic PAH, protein levels of...
23:02 , Apr 10, 2019 |  BC Extra  |  Company News

Gilead cuts cardiopulmonary sales reps

Gilead said it will lay off about 150 cardiopulmonary sales representatives due to the anticipated market entry of generic versions of Letairis ambrisentan and Ranexa ranolazine. The decision was put into motion almost two years...
21:19 , Apr 10, 2019 |  BC Extra  |  Financial News

Rare genetic disease company Homology raises $125M follow-on

Homology raised $125 million in a follow-on priced late Tuesday to advance its pipeline of gene therapies. Homology Medicines Inc. (NASDAQ:FIXX) sold 5.5 million shares at $22.50. The price represents a 24% discount to the...
13:42 , Apr 8, 2019 |  BC Extra  |  Clinical News

United Therapeutics' esuberaprost fails Phase III in PAH

United Therapeutics discontinued development of esuberaprost after the compound failed to meet the primary endpoint in the Phase III BEAT trial to treat pulmonary arterial hypertension. Esuberaprost is a single isomer formulation of beraprost, a...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:25 , Mar 29, 2019 |  BC Week In Review  |  Company News

Sandoz launches first generic Remodulin in the U.S.

Sandoz launched in the U.S. the first generic version of pulmonary arterial hypertension (PAH) drug Remodulin treprostinil from United Therapeutics. The Novartis AG (NYSE:NVS; SIX:NOVN) unit said its generic has 180 days of marketing exclusivity....
13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Opsumit improves right ventricular function in PAH patients

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension. The...
22:13 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

China releases list of rare disease drugs with reduced VAT

China’s ministry of finance revealed a list of 21 rare disease drugs and four APIs which will be eligible for a reduction in value-added tax beginning March 1. The government will reduce the VAT on...